Welcome to the new CiPA site!

CIPA Initiative

The objective of the CIPA initiative is to facilitate the adoption of a new paradigm for assessment of clinical potential of TdP that is not measured exclusively by potency of hERG block and not at all by QT prolongation.

Presentations now available! CiPA Update Meeting May 21-22

Learn more about the recent meeting and view presentations "The Future of the Assessment of Drug-Induced Arrhythmias and the Comprehensive In Vitro Proarrythmia Assay (CiPA)."

In Silico Source Code Now Available!

See the latest publication from the In Silico Work Stream and get access to the in silico model source code here!

 
The new CIPA paradigm will be driven by a suite of mechanistically based in vitro assays coupled to in silico reconstructions of cellular cardiac electrophysiologic activity, with verification of completeness through comparison of predicted and observed responses in human-derived cardiac myocytes. To the extent that the ongoing validation program is successful, we envision petitioning for corresponding changes to regulatory requirements for proarrhythmia assessment and these might include eliminating or waiving the need for the TQT.

About

The objective of the CIPA initiative is to facilitate the adoption of a new paradigm for assessment of clinical potential of TdP that is not measured exclusively by potency of hERG block and not at all by QT prolongation.

Read More

Work Streams

The work streams have recently been initiated and are open to interested participants. See below for more information on how to join. 

Read More

CiPA Steering Team

The Steering Team acts as liaisons between the work streams and the organizations and stakeholders and meets to discuss project milestones.

Read More

CiPA Compounds

The final compound list is available here.

Read More